Hematological Malignancies

First page Previous page 145 Next page Last page

Results of a phase 1 study of 177 Lu-DOTA-HH1 anti body radionuclide (Betalutin) conjugate for patients with relapsed CD37 + non-Hodgkin lymphomas – Lugano 2015

177Lu-DOTA-HH1 (Betalutin)

• Murine mAb HH1 • Chelate to chemical linker DOTA • Beta emitting lutetium-177 (t1/2= 6.7 days)

Made with